Ritonavir

Fluoxetine not effective for COVID-19 patients

by

Evidence shows weak antiviral activity and no improvement in symptom outcomes. Study: Antiviral efficacy of fluoxetine in early symptomatic COVID-19: an open-label, randomised, controlled, adaptive platform trial (PLATCOV). Image Credit: luchschenF/Shutterstock.com In a recent study published in eClinicalMedicine, researchers characterized the antiviral activity of a selective serotonin reuptake inhibitor (SSRI), fluoxetine, in early coronavirus disease 2019 (COVID-19). … Read more

Azvudine beats paxlovid in reducing COVID-19 deaths

by

A large-scale study reveals azvudine’s comparable efficacy to Paxlovid, fewer adverse effects, and potential antitumor benefits in patients with liver cancer. Study: Real‐world effectiveness and safety of oral azvudine versus nirmatrelvir‒ritonavir (Paxlovid) in hospitalized patients with COVID-19: a multicenter, retrospective, cohort study. Image Credit: Cryptographer/Shutterstock.com In a recent study published in the Signal Transduction and Targeted Therapy, a … Read more